CeriBell, Inc. (CBLL)

CeriBell is an early-stage medical device company delivering rapid, AI-assisted brain monitoring for critically ill patients — a high-value niche with limited direct competition — driving 32.5% YoY revenue growth and a perfect 4-of-4 recent EPS beat record. Unanimous analyst Buy coverage and a consensus price target implying ~16% upside reflect strong institutional conviction in the company's commercial ramp. The key risk is a sustained path to profitability, as the company remains loss-making with a negative forward P/E, leaving it vulnerable to sentiment shifts if revenue growth decelerates.

• Continued commercial expansion of the Ceribell brain monitoring platform into new ICU and hospital accounts, with Q3/Q4 revenue updates serving as key proof points for sustaining the 30%+ growth trajectory.
• Potential label expansions or new clinical data publications supporting broader reimbursement coverage, which could materially accelerate payer adoption and average selling price realization.
• Path-to-profitability milestones or operating leverage disclosures in upcoming earnings — any guidance toward breakeven could re-rate the stock meaningfully given current loss-making status.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →